ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
LUM-201 (ibutamoren) - The OraGrowtH212 trial
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 270505" data-attributes="member: 13851"><p>[MEDIA=youtube]aeCHfIQ6IA0[/MEDIA]</p><p></p><p><strong><em>The OraGrowtH212 trial is a global study involving 80 patients in four arms, testing three different doses of a new drug compared to the standard dose of growth hormone. The study aims to measure catchup growth over an extended period, with promising interim results indicating comparable growth to moderate growth hormone deficiency patients.</em></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Highlights:</strong></p><p></p><ul> <li data-xf-list-type="ul"><em><em>Global trial with 80 patients in four arms</em></em></li> <li data-xf-list-type="ul"><em><em>Testing three doses of new drug compared to standard growth hormone</em></em></li> <li data-xf-list-type="ul"><em><em>Safety profile of the drug is outstanding</em></em></li> <li data-xf-list-type="ul"><em><em>End point is catchup growth at six months annualized</em></em></li> <li data-xf-list-type="ul"><em><em>Topline results expected in the fourth quarter</em></em></li> <li data-xf-list-type="ul"><em><em>Robust data set includes patients on drug for up to two years</em></em></li> <li data-xf-list-type="ul"><em><em>Promising interim results showed comparable growth to moderate growth hormone deficiency patients</em></em></li> <li data-xf-list-type="ul"><em><em>Study highly drisked through predictive enrichment markers strategy</em></em></li> <li data-xf-list-type="ul"><em><em>Patients selected based on specific growth hormone and igf1 levels</em></em></li> <li data-xf-list-type="ul"><em><em>Imbalance in growth hormone arm due to younger patients, but overall good outcome predicted</em></em></li> </ul></blockquote><p></p>
[QUOTE="madman, post: 270505, member: 13851"] [MEDIA=youtube]aeCHfIQ6IA0[/MEDIA] [B][I]The OraGrowtH212 trial is a global study involving 80 patients in four arms, testing three different doses of a new drug compared to the standard dose of growth hormone. The study aims to measure catchup growth over an extended period, with promising interim results indicating comparable growth to moderate growth hormone deficiency patients.[/I] Highlights:[/B] [LIST] [*][I][I]Global trial with 80 patients in four arms[/I][/I] [*][I][I]Testing three doses of new drug compared to standard growth hormone[/I][/I] [*][I][I]Safety profile of the drug is outstanding[/I][/I] [*][I][I]End point is catchup growth at six months annualized[/I][/I] [*][I][I]Topline results expected in the fourth quarter[/I][/I] [*][I][I]Robust data set includes patients on drug for up to two years[/I][/I] [*][I][I]Promising interim results showed comparable growth to moderate growth hormone deficiency patients[/I][/I] [*][I][I]Study highly drisked through predictive enrichment markers strategy[/I][/I] [*][I][I]Patients selected based on specific growth hormone and igf1 levels[/I][/I] [*][I][I]Imbalance in growth hormone arm due to younger patients, but overall good outcome predicted[/I][/I] [/LIST] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
LUM-201 (ibutamoren) - The OraGrowtH212 trial
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top